Suffering CNS player flips another losing hand in a last PhII gamble and calls for the axe
Ground down by repeated clinical failures and the collapse of its share price, one of Aptinyx’s last Phase II hands hit the table Monday after the stock closed. And it was another loser.
Aptinyx’s NYX-458 failed to do much better than a placebo in its trial for mild cognitive impairment or mild dementia in Parkinson’s disease or with Lewy bodies over a 12-week period. So the team is going to scrap the program, chop costs and shutter their only other clinical trial for its PTSD drug so they can read the data available and examine what “strategic alternatives” are out there.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
